Webcast Now Available: Successful Abiomed Impella[R] 2.5 High-Risk PCI Procedure at Mount Sinai Medical Center.

For Webcast Replay, Access Entire Live Case at Abiomed Website

DANVERS, Mass. -- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced the webcast of an Impella[R] 2.5 procedure performed on an 85-year-old male with multi-vessel disease at Mount Sinai Medical Center, now available and archived on the Abiomed website (www.abiomed.com).

The webcast was broadcasted live from Mount Sinai Medical Center on July 21, 2009 and presents a successful high-risk percutaneous coronary intervention (PCI) case with Impella 2.5 support, performed by Samir Sharma, M.D., director of the catheterization lab (cath lab) and interventions, and Annapoorna Kini, M.D., associate professor of the cath lab at Mount Sinai Medical Center.

The patient, an 85-year-old male with multi-vessel disease, had a left ventricular ejection fraction (LVEF) of 20 percent, meaning that his heart's left ventricle was only pumping 20 percent of its volume with each beat. A normal LVEF typically ranges from 60 - 65 percent. Impella 2.5 was inserted to maintain left ventricular support and provide hemodynamic stability. "(Impella) gives operators the confidence to achieve good results without worrying about hemodynamic compromise," states Dr. Sharma during the live webcast.

"Mount Sinai Medical Center is renowned for its high volumes and exceptional outcomes," said Michael R. Minogue, Chairman, President and Chief Executive Officer of Abiomed. "We are honored that Impella is considered one of the primary options for hemodynamic support and complete revascularization in high-risk PCI cases."

To view the entire webcast, go to the Abiomed homepage at www.abiomed.com.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release may contain forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Abiomed, Impella and the Abiomed logo are all trademarks of Abiomed. Other company and product names may be trademarks of their respective owners.